169 related articles for article (PubMed ID: 24875798)
1. Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck.
Misiukiewicz K; Bonomi M; Demicco E; Posner M
Ann Oncol; 2014 Aug; 25(8):1667-8. PubMed ID: 24875798
[No Abstract] [Full Text] [Related]
2. Current treatment options for metastatic head and neck cancer.
Price KA; Cohen EE
Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
[TBL] [Abstract][Full Text] [Related]
3. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.
Psyrri A; Rampias T; Vermorken JB
Ann Oncol; 2014 Nov; 25(11):2101-2115. PubMed ID: 25057165
[TBL] [Abstract][Full Text] [Related]
4. Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Khuri FR
Head Neck; 2013 Mar; 35(3):443-53. PubMed ID: 22052826
[TBL] [Abstract][Full Text] [Related]
5. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
[TBL] [Abstract][Full Text] [Related]
6. HUMAN PAPILLOMAVIRUS AND SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Cobzeanu MD
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):7-9. PubMed ID: 27125065
[No Abstract] [Full Text] [Related]
7. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
Burtness B
J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
[No Abstract] [Full Text] [Related]
9. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Szturz P; Seiwert TY; Vermorken JB
J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
[No Abstract] [Full Text] [Related]
10. [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
Dufresne A; Gainet M; Stein U; Guardiola E; Pivot X
Bull Cancer; 2003 Jan; 90(1):39-45. PubMed ID: 12609803
[TBL] [Abstract][Full Text] [Related]
11. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck.
Begum S; Gillison ML; Nicol TL; Westra WH
Clin Cancer Res; 2007 Feb; 13(4):1186-91. PubMed ID: 17317828
[TBL] [Abstract][Full Text] [Related]
12. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Del Barco Morillo E; Mesía R; Adansa Klain JC; Vázquez Fernández S; Martínez-Galán J; Pastor Borgoñon M; González-Rivas C; Caballero Daroqui J; Berrocal A; Martínez-Trufero J; Vera R; Cruz-Hernández JJ;
Oral Oncol; 2016 Nov; 62():54-59. PubMed ID: 27865372
[TBL] [Abstract][Full Text] [Related]
14. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
Markovic A; Chung CH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
[TBL] [Abstract][Full Text] [Related]
15. Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck.
Rubinstein PG; Lindgren V; Setty S; Yao M; Pytynia KB; Radosevich JA; Kadkol SS; Feldman LE
J Clin Oncol; 2011 Mar; 29(9):e222-5. PubMed ID: 21189379
[No Abstract] [Full Text] [Related]
16. Prevalence of human papillomavirus types, viral load and physical status of HPV16 in head and neck squamous cell carcinoma from the South Swedish Health Care Region.
Faust H; Eldenhed Alwan E; Roslin A; Wennerberg J; Forslund O
J Gen Virol; 2016 Nov; 97(11):2949-2956. PubMed ID: 27667722
[TBL] [Abstract][Full Text] [Related]
17. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy.
Magnes T; Melchardt T; Weiss L; Mittermair C; Neureiter D; Klieser E; Gampenrieder S; Moser G; Gaggl A; Greil R; Egle A
PLoS One; 2017; 12(7):e0180995. PubMed ID: 28686697
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
19. HPV-related carcinomas of the head and neck: morphologic features, variants, and practical considerations for the surgical pathologist.
Stevens TM; Bishop JA
Virchows Arch; 2017 Aug; 471(2):295-307. PubMed ID: 28417200
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for recurrent/metastatic head and neck cancers.
Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
Anticancer Drugs; 2017 Apr; 28(4):357-361. PubMed ID: 28166090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
